Crossover study dialysis patients 36-hour study paricalcitol versus doxercalciferol
Clinical suppression of PTH at 36 hours was comparable between treatment arms (63% following paricalcitol therapy and 65% following doxercalciferol therapy).
Serum phosphorus was significantly higher during administration of doxercalciferol (2.12 ± 0.11 mmol/L versus 1.85 ± 0.07 mmol/L).
RCT, patients with stage 3 or 4 CKD treated with doxercalciferol versus placebo.
Mean plasma iPTH level decreased by 46% from baseline after 24 weeks of doxercalciferol treatment (), versus placebo. After 6 weeks, iPTH level decreased with doxercalciferol versus placebo ().
No significant differences in mean serum calcium or phosphorus between the groups.